Cardiff Oncology (CRDF) Interest & Investment Income (2011 - 2026)
Cardiff Oncology (CRDF) posted Interest & Investment Income of $612000.0 for Q4 2025, down 14.53% sequentially from $716000.0 in Q3 2025, and down 22.24% YoY from $787000.0 in Q4 2024.
Cardiff Oncology (CRDF) Interest & Investment Income (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Interest & Investment Income for 8 years, with the latest figure at $612000.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 22.24% year-over-year to $612000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 4.76% YoY) and the FY2025 annual result came in at $3.1 million, down 4.76% from the prior year.
- Interest & Investment Income fell to $612000.0 in Q4 2025 per CRDF's latest filing, from $716000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.1 million in Q3 2023 and troughed at $612000.0 in Q4 2025.
- A 3-year average of $862909.1 and a median of $835000.0 in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income slumped 30.62% in 2024, then grew 3.73% in 2025.
- Over 3 years, Interest & Investment Income stood at $1.0 million in 2023, then slipped by 21.92% to $787000.0 in 2024, then slipped by 22.24% to $612000.0 in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $612000.0, $716000.0, and $835000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | 382,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 382,000.00 |
| Dec 31, 2025 | 612,000.00 |
| Sep 30, 2025 | 716,000.00 |
| Jun 30, 2025 | 835,000.00 |
| Mar 31, 2025 | 941,000.00 |
| Dec 31, 2024 | 787,000.00 |
| Sep 30, 2024 | 741,000.00 |
| Jun 30, 2024 | 805,000.00 |
| Mar 31, 2024 | 926,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.05 Mn |
| Dec 31, 2016 | -9,065.00 |
| Sep 30, 2015 | 17,368.00 |
| Jun 30, 2015 | 9,251.00 |
| Mar 31, 2015 | 6,369.00 |
| Dec 31, 2014 | -7,940.00 |
| Sep 30, 2014 | 3,470.00 |
| Jun 30, 2014 | 2,079.00 |
| Mar 31, 2014 | 2,391.00 |